<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167151</url>
  </required_header>
  <id_info>
    <org_study_id>OCTO-079</org_study_id>
    <secondary_id>2016-002267-33</secondary_id>
    <nct_id>NCT03167151</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)</brief_title>
  <acronym>PemBla</acronym>
  <official_title>A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A parallel group, open label, multi-centre, phase I/II marker-lesion study of intravesical or&#xD;
      intravenous pembrolizumab in recurrent intermediate risk NMIBC. Thirty patients (fifteen in&#xD;
      each of two arms) will be randomised 1:1 to treatment with either intravesical pembrolizumab&#xD;
      (Arm A) or intravenous pembrolizumab (Arm B). The main study will be preceded by a single&#xD;
      institution safety run-in phase involving intra-patient dose escalation in six patients to&#xD;
      confirm the safety and tolerability of intravesical pembrolizumab and the dose to be used in&#xD;
      the randomised phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bladder cancer is the seventh most common cancer in the United Kingdom (UK) and ninth most&#xD;
      common cancer worldwide. New strategies for treating this disease are urgently required to&#xD;
      reduce recurrence and progression rates. Pembrolizumab is a type of immunotherapy drug that&#xD;
      has been approved for use in certain types of melanoma and lung cancer. It is thought to work&#xD;
      by helping the body's immune system to recognise and attack cancer. Drugs that work in a&#xD;
      similar way have shown some encouraging results in studies treating patients with bladder&#xD;
      cancer that has spread to other parts of the body, although they are not currently approved&#xD;
      for treating either advanced or localised bladder cancer.&#xD;
&#xD;
      This trial is being performed to assess the safety and tolerability of giving pembrolizumab&#xD;
      to patients with localised bladder cancer and to study what effects the drug has on the&#xD;
      tumour; Participants will have all but one tumour (referred to as the marker lesion) removed&#xD;
      during their transurethral resection of bladder tumour (TURBT) procedure at the start of the&#xD;
      trial. After trial treatment, a further TURBT procedure will be carried out to remove the&#xD;
      marker lesion, or if the marker lesion is no longer visible, a biopsy will be taken of the&#xD;
      area where the growth was before.&#xD;
&#xD;
      After a safety run in with intra-patient dose escalation of intravesical pembrolizumab&#xD;
      performed in paired patient cohorts, the trial will test two different ways of giving the&#xD;
      pembrolizumab; directly into the bladder (intravesical) with 6 doses being received over 6&#xD;
      weeks and with a further dose approximately 3 weeks later, or into the blood stream via the&#xD;
      veins (intravenous) with a dose being received every 3 weeks for a maximum of 4 doses.&#xD;
&#xD;
      36 eligible participants from across 3 UK centres will be randomly allocated to receive&#xD;
      treatment by one of these ways. Following the end of treatment visit, patients will return to&#xD;
      receiving standard care but receive follow-up for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study failed to recruit within the permitted timeframe&#xD;
  </why_stopped>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">March 26, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities (DLTs) to Assess the Safety, Tolerability and Toxicities of Intravesical Pembrolizumab After Transurethral Resection of Bladder Tumour (TURBT).</measure>
    <time_frame>Adverse event monitoring starts on the day of the TURBT procedure (Day -14) until 90 days post treatment, or 30 days following administration of the last dose of study medication if the subject initiates a new anticancer therapy.</time_frame>
    <description>Adverse events are categorised according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Patients with intermediate risk Non-muscle Invasive Bladder Cancer (NMIBC) were assessed for dose limiting toxicity (DLT) and tolerability.&#xD;
Administration of at least 5 out of 6 treatments was required for the regime to be defined as tolerable.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Correlation Between Expression of Programmed Death Ligand 1 (PD-L1) and Programmed Cell Death 1 (PD-1+) Infiltrating Lymphocytes and Efficacy of Pembrolizumab Therapy After TURBT.</measure>
    <time_frame>Day -14 TURBT, optional Day 50 TURBT, Day 85 TURBT and where applicable optional follow-up period ≤ 24 months</time_frame>
    <description>Pre treatment, during treatment (optional), and post treatment tumour samples Immunohistochemistry and Fluorescence-activated cell sorting (FACS) analysis to measure. Additionally, collection of an optional tumour sample at the time of recurrence or progression for research purposes will be performed if the patient provides consent for this. The optional tumour sample would be collected at the time of a standard care surveillance cystoscopy or resection if the patient had a repeat TURBT in standard care.</description>
  </other_outcome>
  <other_outcome>
    <measure>Definition of Gene Expression Signatures and Genetic Profiles Capable of Predicting Efficacy of Pembrolizumab Treatment in NMIBC Patients.</measure>
    <time_frame>Day 1 pre-treatment</time_frame>
    <description>Gene expression profiling and DNA sequencing on pre-treatment blood and tumour samples to predict efficacy of pembrolizumab treatment in NMIBC patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of T-cell Receptor (TCR) Repertoire and Clonality of Infiltrating T-cells in Resected Tumour Specimens, Urine and Normal Bladder Tissue.</measure>
    <time_frame>Day 1 to 92</time_frame>
    <description>Evaluating the effects of pembrolizumab treatment on the immunological profile and tumour specific immune responses in patients with intermediate risk NMIBC.</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of TCR Repertoire and Clonality of Peripheral Blood Mononuclear Cells (PBMC) Before, During and After Treatment.</measure>
    <time_frame>Day 1 to 92</time_frame>
    <description>Identification of myeloid or T cell responses in the tumour microenvironment associated with the response to treatment with pembrolizumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Cytokines in Blood and Urine.</measure>
    <time_frame>Day 1 to 92</time_frame>
    <description>Identification of myeloid or T cell responses in the tumour microenvironment associated with response to treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Non-muscle Invasive Bladder Cancer (NMIBC)</condition>
  <arm_group>
    <arm_group_label>Arm A Intravesical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravesical Pembrolizumab (solution for infusion) 50-200 mg, given on D1, D8, D15, D22, D29, D36 &amp; D64.&#xD;
Dose to be decided after safety run-in.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Pembrolizumab (solution for infusion), 200mg, given on D1, D22, D43, D64</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Solution for Infusion (Intravesical and Intravenous) 100mg/ 4ml vial</description>
    <arm_group_label>Arm A Intravesical</arm_group_label>
    <arm_group_label>Arm B Intravenous</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible for participation in this trial, the subject must:&#xD;
&#xD;
          1. Be willing and able to provide written informed consent for the trial and comply with&#xD;
             the protocol scheduled follow-up visits and examinations for the duration of the&#xD;
             study.&#xD;
&#xD;
          2. Be ≥ 18 years of age on day of signing informed consent.&#xD;
&#xD;
          3. Have recurrent NMIBC for which adjuvant treatment post TURBT would be a reasonable&#xD;
             treatment option.&#xD;
&#xD;
          4. Main study only: a. Have recurrent, multiple (minimum 2) tumours consistent with&#xD;
             NMIBC.&#xD;
&#xD;
             b. Have at least one lesion of between 5-10mm in size clinically that can be left&#xD;
             un-resected at TURBT as the marker lesion.&#xD;
&#xD;
             c. Have histologically confirmed low grade transitional cell NMIBC at original and any&#xD;
             subsequent diagnosis.&#xD;
&#xD;
          5. Have a normal upper urinary tract (as evidenced by ultrasound or CT urography within 2&#xD;
             years prior to randomisation) and no evidence of tumour in prostatic urethra at&#xD;
             flexible cystoscopy.&#xD;
&#xD;
          6. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Scale.&#xD;
&#xD;
          7. Have adequate organ function as defined below:&#xD;
&#xD;
             Haemoglobin (Hb) ≥ 9 g/dL without transfusion or erythropoietin (EPO) dependency&#xD;
             Absolute neutrophil count (ANC) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Total&#xD;
             bilirubin ≤ 1.5 times the upper limit of normal (ULN) or direct bilirubin &lt; ULN for&#xD;
             subjects with total bilirubin levels &gt; 1.5 x ULN Serum alanine aminotransferase (ALT)&#xD;
             and/or serum aspartate aminotransferase (AST) ≤ 2.5 x ULN Serum creatinine OR Measured&#xD;
             or calculated creatinine clearance ≤ 1.5 x ULN OR&#xD;
&#xD;
             ≥ 60ml/min for subject with creatinine levels &gt; 1.5 x institutional ULN Albumin ≥&#xD;
             25g/L International Normalized Ratio (INR) or Prothrombin Time (PT) and Activated&#xD;
             Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN unless subject is receiving&#xD;
             anticoagulant therapy as long as PT or APTT is within therapeutic range of intended&#xD;
             use of anticoagulants a Creatinine clearance should be calculated as per institutional&#xD;
             standard&#xD;
&#xD;
          8. Female subjects of childbearing potential should have a negative urine or serum&#xD;
             pregnancy test within 72 hours prior to receiving the first dose of study medication.&#xD;
             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy&#xD;
             test will be required.&#xD;
&#xD;
          9. Both male and female subjects of childbearing potential must be willing to use an&#xD;
             adequate method of contraception as outlined in section 5.1 for the course of the&#xD;
             study and until 120 days after the last dose of the study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subject must be excluded from participating in the trial if the subject:&#xD;
&#xD;
          1. Has received prior radiotherapy to the pelvis.&#xD;
&#xD;
          2. Has significant urinary incontinence or known bladder instability.&#xD;
&#xD;
          3. Main study only:&#xD;
&#xD;
               1. Has more than 2 out of 3 of the following present at the current time: i. ≥8&#xD;
                  tumours ii. Tumour ≥3cm in size iii. Frequent recurrence (&gt;1/year)&#xD;
&#xD;
               2. Has a previous history of any of the following: T1 tumour, high grade/G3 tumour,&#xD;
                  carcinoma in situ, multiple recurrent large (&gt;3cm) Ta, G1 or G2 tumours.&#xD;
&#xD;
               3. Had a primary tumour of unknown pathological stage or grade.&#xD;
&#xD;
               4. Has disease for which resection of all visible tumours is not possible.&#xD;
&#xD;
          4. Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 28 days of the first dose of trial treatment.&#xD;
&#xD;
          5. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment. Subjects requiring use of inhaled or intranasal corticosteroids or local&#xD;
             steroid injections would not be excluded.&#xD;
&#xD;
          6. Has a known history of active tuberculosis (TB).&#xD;
&#xD;
          7. Has received intravesical Bacillus Calmette-Guerin (BCG) treatment within 30 days&#xD;
             prior to the first dose of trial treatment.&#xD;
&#xD;
          8. Has hypersensitivity to pembrolizumab or any of its excipients.&#xD;
&#xD;
          9. Has had treatment with any other anti-cancer monoclonal antibody within 28 days prior&#xD;
             to enrolment or who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse&#xD;
             events due to agents administered more than 4 weeks earlier.&#xD;
&#xD;
         10. Has had treatment with prior chemotherapy, targeted small molecule therapy, or&#xD;
             radiation therapy within 2 weeks of administration of study drug or who has not&#xD;
             recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to a previously&#xD;
             administered agent.&#xD;
&#xD;
         11. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer.&#xD;
&#xD;
         12. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Subjects with previously treated brain metastases may participate provided&#xD;
             they are stable (without evidence of progression by imaging for at least four weeks&#xD;
             prior to the first dose of trial treatment and any neurological symptoms have returned&#xD;
             to baseline), have no evidence of new or enlarging brain metastases, and are not using&#xD;
             steroids for a t least 7 days prior to trial treatment. This exception does not&#xD;
             include carcinomatous meningitis which is excluded regardless of clinical stability.&#xD;
&#xD;
         13. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents or immunosuppressive drugs). Replacement&#xD;
             therapy (e.g. thyroxine, insulin or physiologic corticosteroids replacement therapy&#xD;
             for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic&#xD;
             treatment.&#xD;
&#xD;
         14. Has a known history of, or any evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
         15. Has an active or intractable infection requiring systemic therapy.&#xD;
&#xD;
         16. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating Investigator.&#xD;
&#xD;
         17. Has a known psychiatric or substance abuse disorder that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         18. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through to 120 days after the last dose of trial treatment.&#xD;
&#xD;
         19. Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1),&#xD;
             anti-programmed death ligand 1 (anti PD-L1), or anti-programmed death ligand 2&#xD;
             (anti-PD-L2) agent.&#xD;
&#xD;
         20. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         21. Has known active Hepatitis B (e.g. HBsAg reactive) or Hepatitis C (e.g. hepatitis C&#xD;
             virus [HCV] RNA [qualitative] is detected).&#xD;
&#xD;
         22. Has received a live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S Protheroe, MRCP, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital NHS Foundation Trust</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <results_first_submitted>June 19, 2020</results_first_submitted>
  <results_first_submitted_qc>July 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2020</results_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent intermediate risk NMIBC</keyword>
  <keyword>Intravesical Pembrolizumab</keyword>
  <keyword>Intravenous Pembrolizumab</keyword>
  <keyword>Phase I/II</keyword>
  <keyword>Marker-lesion</keyword>
  <keyword>Non-muscle invasive bladder cancer (NMIBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT03167151/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT03167151/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Initially, the plan was to recruit the 6 participants for the safety run-in phase of the study within 6 months. 9 patients, of which 6 were evaluable, were recruited at the Oxford Churchill Hospital site from 02 Mar 2018 until 31 Jan 2019. Due to the issues with slow recruitment, the steering committee decided to end recruitment on 31 Jan 2019</recruitment_details>
      <pre_assignment_details>9 participants were recruited onto the study. However, of the 9 participants, 2 were found to have no tumour present during their surgery and were therefore no longer eligible. A further 1 participant withdrew their consent after they had been recruited. Thus of 9 participants only 6 were eligible for analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Safety run-in Phase Cohort 1</title>
          <description>Cohort 1 in the safety run-in phase. Day 1 starting dose 50mg intravesical pembrolizumab</description>
        </group>
        <group group_id="P2">
          <title>Safety run-in Phase Cohort 2</title>
          <description>Cohort 2 in the safety run-in phase. Day 1 starting dose 100mg intravesical pembrolizumab</description>
        </group>
        <group group_id="P3">
          <title>Safety run-in Phase Cohort 3</title>
          <description>Cohort 3 in the safety run-in phase. Day 1 starting dose 200mg intravesical pembrolizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No evidence of tumour at surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Safety run-in Phase Cohort 1</title>
          <description>Cohort 1 in the safety run-in phase. Day 1 starting dose 50mg intravesical pembrolizumab</description>
        </group>
        <group group_id="B2">
          <title>Safety run-in Phase Cohort 2</title>
          <description>Cohort 2 in the safety run-in phase. Day 1 starting dose 100mg intravesical pembrolizumab</description>
        </group>
        <group group_id="B3">
          <title>Safety run-in Phase Cohort 3</title>
          <description>Cohort 3 in the safety run-in phase. Day 1 starting dose 200mg intravesical pembrolizumab</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="0"/>
                    <measurement group_id="B2" value="66" spread="10.6"/>
                    <measurement group_id="B3" value="81" spread="7.8"/>
                    <measurement group_id="B4" value="73" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White British</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Current</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ex-smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Never smoked</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>Measure Description: ECOG performance status is a scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.&#xD;
Grade 0: fully active. Grade 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature Grade 2: up and about more than 50% of waking hours Grade 3: confined to bed or chair more than 50% of waking hours Grade 4: completely disabled Grade 5: dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Performance Status 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Performance Status 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of primary tumour</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Bladder</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Left renal pelvis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Urothelial</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Dose Limiting Toxicities (DLTs) to Assess the Safety, Tolerability and Toxicities of Intravesical Pembrolizumab After Transurethral Resection of Bladder Tumour (TURBT).</title>
        <description>Adverse events are categorised according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Patients with intermediate risk Non-muscle Invasive Bladder Cancer (NMIBC) were assessed for dose limiting toxicity (DLT) and tolerability.&#xD;
Administration of at least 5 out of 6 treatments was required for the regime to be defined as tolerable.</description>
        <time_frame>Adverse event monitoring starts on the day of the TURBT procedure (Day -14) until 90 days post treatment, or 30 days following administration of the last dose of study medication if the subject initiates a new anticancer therapy.</time_frame>
        <population>Six patients received at least 5 out of 6 scheduled treatments, or withdrew early due to drug-related toxicity, and hence these patients contributed to the DLT and tolerability analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Safety run-in Phase Cohort 1</title>
            <description>Cohort 1 in the safety run-in phase. Day 1 starting dose 50mg intravesical pembrolizumab</description>
          </group>
          <group group_id="O2">
            <title>Safety run-in Phase Cohort 2</title>
            <description>Cohort 2 in the safety run-in phase. Day 1 starting dose 100mg intravesical pembrolizumab</description>
          </group>
          <group group_id="O3">
            <title>Safety run-in Phase Cohort 3</title>
            <description>Cohort 3 in the safety run-in phase. Day 1 starting dose 200mg intravesical pembrolizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose Limiting Toxicities (DLTs) to Assess the Safety, Tolerability and Toxicities of Intravesical Pembrolizumab After Transurethral Resection of Bladder Tumour (TURBT).</title>
          <description>Adverse events are categorised according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Patients with intermediate risk Non-muscle Invasive Bladder Cancer (NMIBC) were assessed for dose limiting toxicity (DLT) and tolerability.&#xD;
Administration of at least 5 out of 6 treatments was required for the regime to be defined as tolerable.</description>
          <population>Six patients received at least 5 out of 6 scheduled treatments, or withdrew early due to drug-related toxicity, and hence these patients contributed to the DLT and tolerability analysis.</population>
          <units>DLTs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation Between Expression of Programmed Death Ligand 1 (PD-L1) and Programmed Cell Death 1 (PD-1+) Infiltrating Lymphocytes and Efficacy of Pembrolizumab Therapy After TURBT.</title>
        <description>Pre treatment, during treatment (optional), and post treatment tumour samples Immunohistochemistry and Fluorescence-activated cell sorting (FACS) analysis to measure. Additionally, collection of an optional tumour sample at the time of recurrence or progression for research purposes will be performed if the patient provides consent for this. The optional tumour sample would be collected at the time of a standard care surveillance cystoscopy or resection if the patient had a repeat TURBT in standard care.</description>
        <time_frame>Day -14 TURBT, optional Day 50 TURBT, Day 85 TURBT and where applicable optional follow-up period ≤ 24 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Definition of Gene Expression Signatures and Genetic Profiles Capable of Predicting Efficacy of Pembrolizumab Treatment in NMIBC Patients.</title>
        <description>Gene expression profiling and DNA sequencing on pre-treatment blood and tumour samples to predict efficacy of pembrolizumab treatment in NMIBC patients.</description>
        <time_frame>Day 1 pre-treatment</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Analysis of T-cell Receptor (TCR) Repertoire and Clonality of Infiltrating T-cells in Resected Tumour Specimens, Urine and Normal Bladder Tissue.</title>
        <description>Evaluating the effects of pembrolizumab treatment on the immunological profile and tumour specific immune responses in patients with intermediate risk NMIBC.</description>
        <time_frame>Day 1 to 92</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Analysis of TCR Repertoire and Clonality of Peripheral Blood Mononuclear Cells (PBMC) Before, During and After Treatment.</title>
        <description>Identification of myeloid or T cell responses in the tumour microenvironment associated with the response to treatment with pembrolizumab.</description>
        <time_frame>Day 1 to 92</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Analysis of Cytokines in Blood and Urine.</title>
        <description>Identification of myeloid or T cell responses in the tumour microenvironment associated with response to treatment</description>
        <time_frame>Day 1 to 92</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event monitoring starts on the day of the TURBT procedure (Day -14) until 90 days post treatment, or 30 days following administration of the last dose of study medication if the subject initiates a new anticancer therapy.</time_frame>
      <desc>The investigator monitored each patient for clinical and laboratory evidence of adverse events on a routine basis throughout the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Safety run-in Phase Cohort 1</title>
          <description>Cohort 1 in the safety run-in phase. Day 1 starting dose 50mg intravesical pembrolizumab</description>
        </group>
        <group group_id="E2">
          <title>Safety run-in Phase Cohort 2</title>
          <description>Cohort 2 in the safety run-in phase. Day 1 starting dose 100mg intravesical pembrolizumab</description>
        </group>
        <group group_id="E3">
          <title>Safety run-in Phase Cohort 3</title>
          <description>Cohort 3 in the safety run-in phase. Day 1 starting dose 200mg intravesical pembrolizumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urgency-Frequency Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash over bilateral shins</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flushes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the issues with slow recruitment, the decision was taken to end the trial after the safety run in phase, before the randomised phase began.&#xD;
This meant only a very small number of patients could be analysed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Andrew S Protheroe</name_or_title>
      <organization>Oxford University Hospitals NHS Foundation Trust</organization>
      <phone>01865 253275</phone>
      <email>andrew.protheroe@oncology.ox.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

